Global Bioenergies Future Growth
Future criteria checks 2/6
Global Bioenergies's earnings are forecast to decline at 4% per annum while its annual revenue is expected to grow at 27.6% per year. EPS is expected to grow by 15.1% per annum.
Key information
-4.0%
Earnings growth rate
15.1%
EPS growth rate
Chemicals earnings growth | 11.9% |
Revenue growth rate | 27.6% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 17 Oct 2024 |
Recent future growth updates
Recent updates
Global Bioenergies SA's (EPA:ALGBE) Intrinsic Value Is Potentially 60% Above Its Share Price
Sep 18Does Global Bioenergies (EPA:ALGBE) Have A Healthy Balance Sheet?
Jun 21Is Global Bioenergies (EPA:ALGBE) Using Debt Sensibly?
Jun 28Global Bioenergies (EPA:ALGBE) Has Debt But No Earnings; Should You Worry?
Oct 11Does Global Bioenergies (EPA:ALGBE) Have A Healthy Balance Sheet?
Oct 25Global Bioenergies (EPA:ALGBE) Shareholders Have Enjoyed An Impressive 187% Share Price Gain
Mar 20Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 1 | -9 | -15 | -7 | 1 |
12/31/2024 | 0 | -9 | -12 | -6 | 1 |
6/30/2024 | 0 | -7 | -5 | -4 | N/A |
3/31/2024 | 2 | -8 | -6 | -6 | N/A |
12/31/2023 | 3 | -9 | -8 | -8 | N/A |
9/30/2023 | 4 | -9 | N/A | N/A | N/A |
6/30/2023 | 4 | -10 | -9 | -8 | N/A |
3/31/2023 | 2 | -11 | -11 | -9 | N/A |
12/31/2022 | 1 | -12 | -12 | -10 | N/A |
9/30/2022 | 1 | -11 | N/A | N/A | N/A |
6/30/2022 | 1 | -10 | -14 | -11 | N/A |
3/31/2022 | 1 | -11 | -14 | -12 | N/A |
12/31/2021 | 1 | -12 | -15 | -12 | N/A |
9/30/2021 | 0 | -12 | N/A | N/A | N/A |
6/30/2021 | 0 | -12 | -30 | -28 | N/A |
3/31/2021 | 0 | -11 | -21 | -19 | N/A |
12/31/2020 | 0 | -11 | -11 | -11 | N/A |
9/30/2020 | 0 | -13 | -4 | -3 | N/A |
6/30/2020 | 0 | -12 | 4 | 5 | N/A |
3/31/2020 | 0 | -12 | -3 | -3 | N/A |
12/31/2019 | 0 | -14 | -11 | -10 | N/A |
9/30/2019 | 1 | -13 | N/A | N/A | N/A |
6/30/2019 | 1 | -12 | -16 | -16 | N/A |
3/31/2019 | 1 | -13 | -12 | -12 | N/A |
12/31/2018 | 1 | -14 | -8 | -7 | N/A |
9/30/2018 | 1 | -16 | N/A | N/A | N/A |
6/30/2018 | 0 | -17 | -5 | -5 | N/A |
3/31/2018 | 0 | -16 | N/A | -7 | N/A |
12/31/2017 | 0 | -14 | N/A | -9 | N/A |
9/30/2017 | 0 | -11 | N/A | N/A | N/A |
6/30/2017 | 1 | -10 | N/A | -6 | N/A |
3/31/2017 | 1 | -10 | N/A | -8 | N/A |
12/31/2016 | 1 | -11 | N/A | -9 | N/A |
9/30/2016 | 0 | -11 | N/A | N/A | N/A |
6/30/2016 | 1 | -11 | N/A | -9 | N/A |
3/31/2016 | 1 | -11 | N/A | -10 | N/A |
12/31/2015 | 1 | -10 | N/A | -9 | N/A |
9/30/2015 | 1 | -9 | N/A | N/A | N/A |
6/30/2015 | 1 | -8 | N/A | -8 | N/A |
3/31/2015 | 2 | -7 | N/A | -8 | N/A |
12/31/2014 | 2 | -6 | N/A | -7 | N/A |
9/30/2014 | 2 | -6 | N/A | N/A | N/A |
6/30/2014 | 2 | -6 | N/A | -7 | N/A |
3/31/2014 | 1 | -6 | N/A | -6 | N/A |
12/31/2013 | 1 | -5 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALGBE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALGBE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALGBE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALGBE's revenue (27.6% per year) is forecast to grow faster than the French market (5.5% per year).
High Growth Revenue: ALGBE's revenue (27.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALGBE's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 09:46 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Global Bioenergies SA is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Markus Mayer | Baader Helvea Equity Research |
Mark Cartlich | Edison Investment Research |
Stephanie Lefebvre | Gilbert Dupont |